
About
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with debilitating symptoms. The program includes the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis. The ARCHER Program studied CardiolRx™ in acute myocarditis, which is a significant cause of heart failure in young adults. The Company is also developing CRD-38, a novel drug formulation for inflammatory heart disease, including heart failure.
Verified company data
- Cash position
- $ 27,673,191
- Shares outstanding
- 111872084
- Fully diluted shares
- 120.66m
- Projects
CardiolRx™ (cannabidiol) oral solution is in clinical development for use in the treatment of heart disease. CardiolRx™ attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome, which is known to play an important role in the inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. CardiolRx™ is pharmaceutically manufactured under cGMP to meet the highest standards for product purity, consistency, and stability. A Phase I safety and pharmacokinetic study of single and multiple ascending doses of CardiolRx™ was completed and demonstrated that CardiolRx™ was safe and generally well tolerated at all dose levels, with no serious adverse events reported. The results supported the Company’s two Investigational New Drug Application authorizations from the United States Food and Drug Administration to conduct two Phase II studies in rare heart diseases: recurrent pericarditis and acute myocarditis. The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx™ is also eligible for FDA ODD in acute myocarditis and European Medicine Agency orphan medicine designations for recurrent pericarditis and acute myocarditis.
CRD-38 is a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. We are undertaking IND-enabling activities to support clinical evaluation of CRD-38 as a therapeutic strategy in heart failure care. We are currently developing CRD-38 that is intended to improve the pharmacokinetic profile compared to existing formulations. Subcutaneous administration has the potential to allow for a lower dose of drug to be delivered with less frequent administration, while achieving the same or greater therapeutic effect. Our research collaborators have shown that cannabidiol, when administered subcutaneously, is effective in a pre-clinical model of heart failure. The subcutaneous approach is practical and widely used in human medicine although the formulation requires specific characteristics. We have successfully developed a formulation that meets these required characteristics. Currently, this formulation is undergoing pharmacokinetic testing.
- Leadership
David Elsley (CEO, Founder of Vasogen Inc., with extensive experience in biotechnology and management of clinical trials for anti-inflammatory therapies.), Andrew Hamer (Chief Medical Officer, Former Executive Director at Amgen Inc. with a strong background in cardiology and clinical trial leadership.)
Verified data last updated:
Recent filings
- 52-109F2 - Certification of interim filings - CFO (E)
- MD&A
- Interim financial statements/report
- Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC · Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC (QuoteMedia 6689978877043273)
- Consent letter of issuer's legal counsel
- Company filing
- Other material contract(s)
- Auditors' consent letter
Investor FAQ
The most recent document index entries include a 2026-11-12 set of filings covering other, MD&A, and financial materials, and a 2026-11-03 press release announcing an At-The-Market Equity Offering Program with Jefferies LLC. Earlier items include a 2026-09-23 press release and a 2026-09-16 filing. The specific contents of the 2026-11-12 and other 2026-11-03 and 2026-09 documents are not summarized in the available verified company data.
The MAVERIC Program evaluates CardiolRx™ for recurrent pericarditis and includes the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The ARCHER Program studied CardiolRx™ in acute myocarditis. The Phase I safety and pharmacokinetic study of CardiolRx™ was completed, with no serious adverse events reported, and supported two Phase II studies in recurrent pericarditis and acute myocarditis. Clinical evaluation of CRD-38 in heart failure is not yet reported as underway, as IND-enabling activities and pharmacokinetic testing are ongoing.
Answers last refreshed: